New York City is Taking on Shady Subscriptions
And TINA.org is all for it.
Remdesivir
Case Name (Date)
Fust et al. v. Gilead Sciences, Inc.
23-at-1244, E.D. Cal.
(Sept. 2023)
Product/Service
Remdesivir
Allegations
Falsely marketing Remdesivir as safe and effective against COVID-19 without disclosing its limitations and adverse events, including fatalities
Status
Pending
The Latest
What You Should Know about Kalshi
Prediction market faces legal challenges on multiple fronts.
NJ tax dollars spent on ‘Blue Ribbon’ school awards that critics call deceptive
Julie O’Connor, NJ Spotlight News
The Regulatory Loopholes Behind Prevagen’s Rise
Sara Talpos, Med Shadow
CATrends: Tequilas Marketed as 100% Agave
Ingredient claims come into the limelight.